Clinical Trials List
2023-10-31 - 2027-12-31
Phase II
Recruiting4
ICD-10C76.0
Malignant neoplasm of head, face and neck
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9195.0
Malignant neoplasm of other and ill-defined sites of head, face and neck
-
Trial Applicant
GlaxoSmithKline
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hsiang-Fong Kao 無
- RUEY-LONG HONG 無
- 廖斌志 無
- 陽明翰 無
- YA-FANG CHEN 無
- 黃彥霖 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 顏志傑 無
- Shang-Yin Wu 無
- 劉奕廷 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
300 participants
